PF-06651600

Unassigned

New Medicines

Moderate-to-severe alopecia areata

Information

New molecular entity
Pfizer
Pfizer

Development and Regulatory status

None
None
Phase III Clinical Trials

Category

Janus kinase-3 (JAK3) inhibitor
In the UK, alopecia areata is estimated to affect about 15 in 10,000 people. [1]
Moderate-to-severe alopecia areata
Oral